睿知中国医院研究地图
候选清单

即将招募淋巴瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由上海交通大学医学院附属瑞金医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方上海交通大学医学院附属瑞金医院Ruijin Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06646666,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically confirmed as B-cell non-Hodgkin lymphoma, including:

    入选标准第 3 条

  3. Refractory: At least partial response (PR) after the last chemotherapy or relapse within 12 months after autologous transplantation.

    入选标准第 11 条

    Relapsed: Complete response (CR) after the last chemotherapy, followed by relapse before enrollment, or relapse or progression 12 months or longer after autologous transplantation.

    入选标准第 12 条

    Received lenalidomide, calcineurin inhibitors, chemotherapy (e.g., methotrexate, cyclophosphamide, ifosfamide, nitrogen mustard, or melphalan), mycophenolate, thalidomide, immunosuppressive antibodies (e.g., anti-TNF, anti-IL6, or anti-IL6R), radiation therapy, or any drug that binds FKBP12 (e.g., rapamycin, tacrolimus, everolimus) within 4 weeks prior to PBMC collection.

    排除标准第 17 条

  4. ECOG score = 2

    入选标准第 16 条

  5. Creatinine clearance < 60 mL/min

    入选标准第 19 条

    ALT or AST > 2× upper limit of normal (ULN)

    入选标准第 20 条

    Hemoglobin ≥ 80 g/L

    入选标准第 26 条

    Platelets ≥ 50 × 10\^9/L

    入选标准第 27 条

    ALT/AST ≤ 5 × ULN and total bilirubin < 2 × ULN

    入选标准第 28 条

    Creatinine clearance ≥ 30 mL/min

    入选标准第 29 条

  6. Measurable target lesions: lymph nodes ≥ 15 mm in longest diameter, or extranodal lesions > 10 mm.

    入选标准第 22 条

  7. Chronic HBV carriers with HBV DNA ≥ 500 IU/mL.

    排除标准第 5 条

    Positive HCV RNA in patients with positive HCV antibodies.

    排除标准第 6 条

    Positive HIV antibodies (HIV-Ab).

    排除标准第 7 条

    History of malignancies other than the indication for this trial within the last 5 years, except for in situ cancers (e.g., cervical, bladder, breast) or non-melanoma skin cancer.

    排除标准第 15 条

  8. Pregnant or breastfeeding women, or men or women of childbearing potential unwilling to use contraception during the trial and for 2 years after RJ CAR-T 002 cell infusion.

    排除标准第 18 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06646666,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Willingly sign the informed consent form.
  2. Age ≥ 18 years, any gender.
  3. Histologically confirmed as B-cell non-Hodgkin lymphoma, including:
  4. Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (DLBCL-NOS)
  5. Transformed follicular lymphoma (tFL)
  6. High-grade B-cell lymphoma (HGBL) with MYC, BCL2, and/or BCL6 rearrangements
  7. High-grade B-cell lymphoma not otherwise specified (HGBL-NOS)
  8. Primary mediastinal large B-cell lymphoma (PMBL)
  9. Follicular lymphoma grade 3b (FL3b)
  10. Patients must have experienced at least one line of treatment for relapsed or refractory disease, meeting the following definitions:
  11. Refractory: At least partial response (PR) after the last chemotherapy or relapse within 12 months after autologous transplantation.
  12. Relapsed: Complete response (CR) after the last chemotherapy, followed by relapse before enrollment, or relapse or progression 12 months or longer after autologous transplantation.
  13. Maximum tumor diameter (long axis) > 4 cm.
  14. Evaluator determines that the patient does not meet HDCT/ASCT criteria and meets at least one of the following:
  15. Age ≥ 60 years
  16. ECOG score = 2
  17. FEV1% or DLCO% ≤ 60%
  18. LVEF < 50%
  19. Creatinine clearance < 60 mL/min
  20. ALT or AST > 2× upper limit of normal (ULN)
  21. Patient unwilling to receive high-dose chemotherapy and autologous stem cell transplantation.
  22. Measurable target lesions: lymph nodes ≥ 15 mm in longest diameter, or extranodal lesions > 10 mm.
  23. Expected survival ≥ 12 weeks.
  24. Laboratory tests must meet the following requirements at screening:
  25. Lymphocyte count ≥ 0.1 × 10\^9/L
  26. Hemoglobin ≥ 80 g/L
  27. Platelets ≥ 50 × 10\^9/L
  28. ALT/AST ≤ 5 × ULN and total bilirubin < 2 × ULN
  29. Creatinine clearance ≥ 30 mL/min
  30. Lung function: ≤ CTCAE grade 1 dyspnea, and oxygen saturation (SpO2) ≥ 92% in room air.
  31. LVEF ≥ 40%
  32. Patients with primary central nervous system lymphoma are allowed (secondary CNS lymphoma is not allowed).
  33. Sufficient venous access for apheresis, and no other contraindications for blood cell separation; female participants of childbearing potential must have a negative pregnancy test at screening.

排除标准:Exclusion Criteria:

  1. History of allergy to any component of the cellular product or study treatment.
  2. History of allogeneic hematopoietic stem cell transplantation.
  3. History of organ transplantation.
  4. Patients with active viral hepatitis requiring treatment, including:
  5. Chronic HBV carriers with HBV DNA ≥ 500 IU/mL.
  6. Positive HCV RNA in patients with positive HCV antibodies.
  7. Positive HIV antibodies (HIV-Ab).
  8. Positive Treponema pallidum antibodies (TP-Ab).
  9. Elevated CMV DNA or EBV DNA above normal limits.
  10. Clinical significance of CNS diseases
  11. Presence of active primary central nervous system lymphoma.
  12. Prior treatment with other genetically modified T-cell therapies or CAR-T therapies.
  13. Severe genetic diseases or autoimmune diseases (e.g., systemic lupus erythematosus).
  14. Thromboembolic events (e.g., myocardial infarction, pulmonary embolism, deep vein thrombosis) within 6 months prior to screening.
  15. History of malignancies other than the indication for this trial within the last 5 years, except for in situ cancers (e.g., cervical, bladder, breast) or non-melanoma skin cancer.
  16. Active infections requiring systemic treatment or uncontrolled infections.
  17. Received lenalidomide, calcineurin inhibitors, chemotherapy (e.g., methotrexate, cyclophosphamide, ifosfamide, nitrogen mustard, or melphalan), mycophenolate, thalidomide, immunosuppressive antibodies (e.g., anti-TNF, anti-IL6, or anti-IL6R), radiation therapy, or any drug that binds FKBP12 (e.g., rapamycin, tacrolimus, everolimus) within 4 weeks prior to PBMC collection.
  18. Pregnant or breastfeeding women, or men or women of childbearing potential unwilling to use contraception during the trial and for 2 years after RJ CAR-T 002 cell infusion.
  19. Participation in other drug clinical trials (e.g., new drug trials, registrational studies, investigator-initiated trials) within 4 weeks prior to PBMC collection.
  20. Researcher's judgment that the patient is unsuitable for the trial (e.g., poor compliance, drug abuse).
  21. Vaccination with live or attenuated vaccines within 3 months prior to PBMC collection, or expected vaccination during the trial.

引自 ClinicalTrials.gov, NCT06646666, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06646666,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06646666